Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials

被引:18
作者
Viala-Danten, Muriel [1 ]
Dubois, Dominique [2 ]
Gilet, Helene [1 ]
Martin, Silas [3 ]
Peeters, Katrien [4 ]
Cella, David [5 ]
机构
[1] Mapi Values, F-69003 Lyon, France
[2] Johnson & Johnson Pharmaceut Serv, B-2340 Beerse, Belgium
[3] Johnson & Johnson Pharmaceut Serv LLC, Raritan, NJ 07090 USA
[4] Johnson & Johnson Pharmaceut Serv Tibotec, Hlth Econ & Outcomes Res, B-2800 Mechelen, Belgium
[5] Res & Educ CORE, Evanston NW Healthcare, Ctr Outcomes, Evanston, IL 60201 USA
关键词
Health-related quality of life; HIV/AIDS; Psychometric properties; FAHI questionnaire; QUALITY-OF-LIFE; EXPERIENCED HIV-1-INFECTED PATIENTS; HEALTH-STATUS; ANTIRETROVIRAL THERAPY; TMC125; ETRAVIRINE; DOUBLE-BLIND; VALIDATION; OUTCOMES; HIV/AIDS; AIDS;
D O I
10.1007/s11136-010-9674-9
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
To evaluate psychometric properties of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire, a 47-item disease-specific instrument evaluating Health-Related Quality of Life (HRQL) in human immunodeficiency virus (HIV)-infected patients. Treatment-experienced HIV-infected patients from two clinical programmes (N = 565; N = 1,096) completed the FAHI at Baseline and after 24 weeks of treatment. Psychometric properties of the FAHI were assessed in both trial populations, including minimal important differences (MIDs) calculations. Links between HRQL assessed by FAHI Total score, and biological endpoints were explored by regression analysis and mean score comparisons. Cronbach's alphas ranged from 0.72 to 0.94. Most items met convergent and discriminant validity criteria. Better FAHI scores were seen for patients in earlier HIV stages. Responsiveness was demonstrated with changes in FAHI scores significantly linked to change in EQ-5D score. Depending on methods used, MIDs ranged from 3.2 to 14 for FAHI Total score. Small association was found between FAHI Total score and CD4 count and viral load (r-square < 3%). Mean changes in FAHI scores were not statistically related to viral response. The FAHI demonstrated acceptable psychometric properties in two independent populations. HRQL assessment enabled detection of changes in patients' health status not revealed by traditional efficacy endpoints.
引用
收藏
页码:1215 / 1227
页数:13
相关论文
共 50 条
  • [1] Anti-HIV therapy: Current and future directions
    Agrawal, Lokesh
    Lu, Xihua
    Jin, Qingwen
    Alkhatib, Ghalib
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (16) : 2031 - 2055
  • [2] BERZON RA, 1998, EVALUATING OUTCOMES, V3
  • [3] Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system
    Bonomi, AE
    Cella, DF
    Hahn, EA
    Bjordal, K
    SpernerUnterweger, B
    Gangeri, L
    Bergman, B
    WillemsGroot, J
    Hanquet, P
    Zittoun, R
    [J]. QUALITY OF LIFE RESEARCH, 1996, 5 (03) : 309 - 320
  • [4] Health-related quality of life and virologic outcomes in an HIV clinic
    Call, SA
    Klapow, JC
    Stewart, KE
    Westfall, AO
    Mallinger, AP
    DeMasi, RA
    Centor, R
    Saag, MS
    [J]. QUALITY OF LIFE RESEARCH, 2000, 9 (09) : 977 - 985
  • [5] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58
  • [6] Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument
    Cella, DF
    McCain, NL
    Peterman, AH
    Mo, F
    Wolen, D
    [J]. QUALITY OF LIFE RESEARCH, 1996, 5 (04) : 450 - 463
  • [7] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [8] Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
  • [9] A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials
    Clayson, Darren J.
    Wild, Diane J.
    Quarterman, Paul
    Duprat-Lomon, Isabelle
    Kubin, Maria
    Coons, Stephen Joel
    [J]. PHARMACOECONOMICS, 2006, 24 (08) : 751 - 765
  • [10] Cohen J., 1977, Statistical Power Analysis for the Behavioral Sciences